文献速递心脑血管急症消化、代谢与肾脏急症

卡格列净与其他非格列净类降糖药的心血管结局比较:基于人群的队列研究

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.
PubMed 文献 · BMJ · 2018-02-06
一句话结论在2型糖尿病患者中,与DPP-4抑制剂、GLP-1受体激动剂或磺脲类相比,卡格列净与较低的心衰住院风险相关,而心梗或卒中复合终点风险相似。

该研究为基于美国大型商业医保数据库的回顾性队列研究,纳入2013年4月至2015年9月间启动卡格列净或非格列净类降糖药(DPP-4抑制剂、GLP-1受体激动剂或磺脲类)的18岁以上2型糖尿病患者,构建三个1:1倾向评分匹配队列。主要终点为心衰住院和复合心血管终点(急性心梗、缺血性卒中或出血性卒中住院)。结果显示,与DPP-4抑制剂、GLP-1受体激动剂和磺脲类相比,卡格列净的心衰住院风险比分别为0.70、0.61和0.51,复合心血管终点风险比分别为0.89、1.03和0.86,后者的置信区间均包含1。结论认为卡格列净与较低的心衰住院风险相关,而心梗或卒中风险与三类对照药物相似。

要点

  • 与DPP-4抑制剂相比,卡格列净的心衰住院风险比为0.70(95%CI 0.54-0.92),匹配队列为17 667对。
  • 与GLP-1受体激动剂相比,卡格列净的心衰住院风险比为0.61(95%CI 0.47-0.78),匹配队列为20 539对。
  • 与磺脲类相比,卡格列净的心衰住院风险比为0.51(95%CI 0.38-0.67),匹配队列为17 354对。
  • 卡格列净与三类对照药的复合心血管终点(急性心梗、缺血性卒中或出血性卒中住院)风险比分别为0.89(0.68-1.17)、1.03(0.79-1.35)、0.86(0.65-1.13),均未达统计学显著。
  • 进一步调整基线糖化血红蛋白及按既往心血管疾病或心衰分组的亚组分析结果相似。

适用人群与场景

  • 18岁及以上、2013年4月至2015年9月间启动卡格列净或非格列净类降糖药(DPP-4抑制剂、GLP-1受体激动剂或磺脲类)的2型糖尿病患者,数据来自美国大型去标识商业医保数据库(Optum Clinformatics Datamart)的全国样本。

研究设计与关键结果

  • 研究设计为基于人群的回顾性队列研究,构建三个1:1倾向评分匹配队列,分别比较卡格列净与DPP-4抑制剂(17 667对)、GLP-1受体激动剂(20 539对)和磺脲类(17 354对),匹配调整100余项基线特征。
  • 主要终点为心衰住院和复合心血管终点(急性心肌梗死、缺血性卒中或出血性卒中住院)。
  • 在30个月期间,卡格列净与DPP-4抑制剂相比心衰住院风险比为0.70(95%CI 0.54-0.92),与GLP-1受体激动剂相比为0.61(0.47-0.78),与磺脲类相比为0.51(0.38-0.67)。
  • 卡格列净与DPP-4抑制剂相比复合心血管终点风险比为0.89(0.68-1.17),与GLP-1受体激动剂相比为1.03(0.79-1.35),与磺脲类相比为0.86(0.65-1.13)。
  • 进一步调整基线糖化血红蛋白水平的敏感性分析及按有无既往心血管疾病或心衰分组的亚组分析结果相似。

证据类型、等级与局限

  • 证据类型:基于人群的回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在常规实践中,对于2型糖尿病患者,与DPP-4抑制剂、GLP-1受体激动剂或磺脲类相比,卡格列净可能与较低的心衰住院风险相关,而心梗或卒中风险相似。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the cardiovascular safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus, in direct comparisons with DPP-4 inhibitors (DPP-4i), GLP-1 receptor agonists (GLP-1RA), or sulfonylureas, as used in routine practice.

DESIGN: Population based retrospective cohort study.

SETTING: Nationwide sample of patients with type 2 diabetes from a large de-identified US commercial healthcare database (Optum Clinformatics Datamart).

PARTICIPANTS: Three pairwise 1:1 propensity score matched cohorts of patients with type 2 diabetes 18 years and older who initiated canagliflozin or a comparator non-gliflozin antidiabetic agent (ie, a DPP-4i, a GLP-1RA, or a sulfonylurea) between April 2013 and September 2015.

MAIN OUTCOME MEASURES: The primary outcomes were heart failure admission to hospital and a composite cardiovascular endpoint (comprised of being admitted to hospital for acute myocardial infarction, ischemic stroke, or hemorrhagic stroke). Hazard ratios and 95% confidence intervals were estimated in each propensity score matched cohort controlling for more than 100 baseline characteristics.

RESULTS: During a 30 month period, the hazard ratio for heart failure admission to hospital associated with canagliflozin was 0.70 (95% confidence interval 0.54 to 0.92) versus a DPP-4i (n=17 667 pairs), 0.61 (0.47 to 0.78) versus a GLP-1RA (20 539), and 0.51 (0.38 to 0.67) versus a sulfonylurea (17 354 ). The hazard ratio for the composite cardiovascular endpoint associated with canagliflozin was 0.89 (0.68 to 1.17) versus a DPP-4i, 1.03 (0.79 to 1.35) versus a GLP-1RA, and 0.86 (0.65 to 1.13) versus a sulfonylurea. Results were similar in sensitivity analyses further adjusting for baseline hemoglobin A1c levels and in subgroups of patients with and without prior cardiovascular disease or heart failure.

CONCLUSIONS: In this large cohort study, canagliflozin was associated with a lower risk of heart failure admission to hospital and with a similar risk of myocardial infarction or stroke in direct comparisons with three different classes of non-gliflozin diabetes treatment alternatives as used in routine care.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Patorno E, Goldfine AB, Schneeweiss S, et al. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ. 2018. PMID: 29437648. doi:10.1136/bmj.k119

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。